Bladder Cancer: Novel Insights and Recent Approvals

Marc R. Matrana, MD, MSc, FACP System Medical Director, Precision Medicine Endowed Professor of Experimental Therapeutics Ochsner MD Anderson Cancer Center New Orleans, Louisiana

Professor, Faculty of Medicine The University of Queensland Medical School Brisbane, Australia

Friday, July 19, 2024 New Orleans Summer Cancer Meeting



Ochsner MDAnderson Cancer Center


Making Cancer History®



Recent Progress in Bladder Cancer

- New SOC in First Line Met Urothelial Cancer (enfortumab vedotin + pembrolizumab)
- FDA Approval of nivolumab + gemcitabine/cisplatin for Met Urothelial Cancer
- FDA Approval of Novel Gene Therapy in NMIBC (nadofaragene firadenovec)
- FDA Approval of Novel Immunotherapy in NMIBC (nogapendekin alfa inbakicept-pmln)
- New data on a Novel Gene Therapy/Immunotherapy Combo in NMIB (cretostimogene grenadenorepvec and pembrolizumab)


EV-302/KEYNOTE-A39 (NCT04223856)



Stratification factors: cisplatin eligibility (eligible/ineligible), PD-L1 expression (high/low), liver metastases (present/absent)


Cisplatin eligibility and assignment/dosing of cisplatin vs carboplatin were protocol-defined; patients received 3-week cycles of EV (1.25 mg/kg; IV) on Days 1 and 8 and P (200 mg; IV) on Day 1

Statistical plan for analysis: the first planned analysis was performed after approximately 526 PFS (final) and 356 OS events (interim); if OS was positive at interim, the OS interim analysis was considered final



Progression-Free Survival per BICR

Risk of progression or death was reduced by 55% in patients who received EV+P



Subgroup Analysis of PFS per BICR


PFS benefit in select pre-specified subgroups was consistent with results in overall population

	Events/N			
Subgroup	EV+P	Chemotherapy	Hazard Ratio (95% CI)	
Overall	223/442	307/444	⊢ ∎→1	0.45 (0.38-0.54)
Age				
<65 years	75/144	88/135		0.45 (0.32-0.62)
≥65 years	148/298	219/309	⊢ ∎→1	0.45 (0.36-0.56)
Sex				
Female	55/98	74/108		0.49 (0.34-0.71)
Male	168/344	233/336		0.44 (0.36-0.54)
ECOG PS				. ,
0	93/223	146/215		0.36 (0.28-0.48)
1-2	130/219	161/227	⊢ ∎−−1	0.53 (0.42-0.68)
Primary disease site of origin				
Upper tract	69/135	70/104	⊢	0.50 (0.35-0.71)
Lower tract	152/305	236/339		0.44 (0.35-0.54)
Liver metastases				1. The second
Present	66/100	78/99	⊢	0.53 (0.38-0.76)
Absent	157/342	229/345	⊢ ∎−1	0.43 (0.35-0.52)
PD-L1 expression				
Low (CPS <10)	105/184	127/185		0.50 (0.38-0.65)
High (CPS ≥10)	116/254	176/254		0.42 (0.33-0.53)
Cisplatin eligibility				, , ,
Eligible	117/244	149/234		0.48 (0.38-0.62)
Ineligible	106/198	158/210	⊢ ∎−−1	0.43 (0.33-0.55)
•				
		0.1	1	5
			Favors EV+P Favors chemoth	ierapy —

https://www.urotoday.com/conference-highlights/esmo-2023-bladder-cancer/147538-esmo-2023-ev-302-keynote-a39-enfortumab-vedotin-in-combination-with-pembrolizumab-ev-p-vs-chemotherapy-in-previously-untreated-locally-advanced-metastatic-urothelial-carcinoma.html


Overall Survival

Risk of death was reduced by 53% in patients who received EV+P



Confirmed Overall Response per BICR

Significant improvement in objective response rate was observed with EV+P




	EV+P (N=437)	Chemotherapy (N=441)	
Confirmed ORR, n (%) (95% Cl)	296 (67.7) (63.1-72.1)	196 (44.4) (39.7-49.2)	
2-sided P value	<0.00001		
Best overall response ^a , n (%)			
Complete response	127 (29.1)	55 (12.5)	
Partial response	169 (38.7)	141 (32.0)	
Stable disease	82 (18.8)	149 (33.8)	
Progressive disease	38 (8.7)	60 (13.6)	
Not evaluable/No assessment ^b	21 (4.8)	36 (8.2)	

EV Treatment-Related Adverse Events of Special Interest*

Majority of treatment-related AESIs were low grade


	EV+P (N=440) n (%)		Chemotherapy (N=433) n (%)	
	Any grade	Grade ≥3	Any grade	Grade ≥3
Skin reactions	294 (66.8)	68 (15.5)	60 (13.9)	1 (0.2)
Peripheral neuropathy	278 (63.2)	30 (6.8)	53 (12.2)	0 (0.0)
Sensory events	260 (59.1)	19 (4.3)	51 (11.8)	0 (0.0)
Motor events	44 (10.0)	12 (2.7)	5 (1.2)	0 (0.0)
Ocular disorders	94 (21.4)	0 (0.0)	12 (2.8)	0 (0.0)
Dry eye	82 (18.6)	0 (0.0)	8 (1.8)	0 (0.0)
Hyperglycemia	57 (13.0)	27 (6.1)	3 (0.7)	0 (0.0)
Infusion-related reactions	9 (2.0)	0 (0.0)	9 (2.1)	0 (0.0)




Median (range) study follow-up, 33.6 (7.4-62.4) months

Primary endpoints: OS, PFS per BICR Key secondary endpoints: OS and PFS by PD-L1 ≥ 1%,^d HRQoL Key exploratory endpoints: ORR per BICR, safety

OS (primary endpoint)




PFS per BICR (primary endpoint)



ORR (95% CI) and BOR per BICR^a CR 📕 📕 70 57.6% PR (51.8-63.2)60 43.1% 50 21.7% (37.5 - 48.9)Patients (%) 40 11.8% 30 20 35.9% 31.3% 10 0 28.3% SD 25.3% PD 9.5% 12.8% UEb 7.6% 15.8% NIVO+GC GC (N = 304)(N = 304)


Duration of objective response per BICR



Nadofaragene firadenovec-vncg

- The FDA has approved nadofaragene firadenovec-vncg as the first gene therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)—unresponsive non—muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
- Approval was based on CS-003 trial.
 - CR = 51% (n = 50/98; 95% CI, 41%-61%) by 3 months in those with CIS with or without concomitant high-grade Ta or T1 disease.
 - Median DOR was 9.7 months (range, 3-52+)
 - Of those who achieved CR, 46% (n = 23) continued to be free of high-grade recurrence at 12 months.

Nadofaragene Firadenovec



Nogapendekin alfa inbakicept-pmln

- Nogapendekin alfa inbakicept-pmln is a first-in-class interleukin (IL)-15 receptor super agonist.
- It is now approved in combination with BCG for adults with BCGunresponsive NMIBC with carcinoma in situ with or without papillary tumors.

Nogapendekin alfa inbakicept-pmln

- Approval was based on data from the single-arm, multicenter QUILT-3.032 trial.
- Trial included 77 evaluable patients who received the novel immunotherapy along with BCG maintenance therapy for up to 37 months.
- CR = 62% (95% CI 51-73)
- 58% of responders had DOR >/= 1 year
- 40% of responders had DOR >/= 2 years

Nogapendekin alfa inbakicept-pmln

N-803: First-in-Class IgG1-Fc IL-15 Cytokine Agonist



Unique Mechanisms of Action

IL-15N72D

IL-15 N72D mutation enhances binding to IL-2Rβ, driving proliferation and activation of NK and T cells

IL-15Ra

Allows transpresentation selectively to only IL-2Rβγ chain of NK and CD8⁺ T cells without binding to Tregs

IgG1 Fc

Increases half-life and lymphoid recycling and homing Specific binding to NK, CD8⁺ T cells, dendritic cells and macrophages

Cretostimogene grenadenorepvec + pembrolizumab

- Direct cell killing
 - The virus selectively infects and replicates in tumor cells, which can cause them to lyse.
- Immune-mediated cell killing
 - The virus also expresses granulocyte-macrophage colony stimulating factor (GM-CSF), which can stimulate a cytotoxic T cell response against the tumor cells. When cancer cells rupture, they release tumor antigens and GM-CSF, which can trigger a systemic immune response.

Cretostimogene grenadenorepvec + pembrolizumab

- 2 CORE-001 trial presented at the 2024 ASCO
- 35-patient intention-to-treat (ITT) population; BCG–unresponsive non–muscle-invasive bladder cancer (NMIBC)
- CR rate was 83%
- Over half of CRs maintained their response at 24 months
- PFS was 100%.

Ongoing Trials of Interest

- Olaparib in Patients With Metastatic/Advanced Urothelial Carcinoma With DNA-Repair Defects
- MEDI4736 (Durvalumab) and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
- Multiple ctDNA studies
- ClinicalTrials.gov

Conclusions

- New treatment modalities (ADCs, novel immunotherapies, and gene therapies) now offer new hope to patients with bladder cancer.
- Defining novel molecular targets and new biomarkers of response will allow us to better personalize innovative treatments options for patients with bladder cancer.